Analysts Conflicted on These Healthcare Names: Akebia Therapeutics (AKBA), Idexx Laboratories (IDXX) and Arvinas Holding Company (ARVN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Akebia Therapeutics (AKBA – Research Report), Idexx Laboratories (IDXX – Research Report) and Arvinas Holding Company (ARVN – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Akebia Therapeutics (AKBA)
In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Akebia Therapeutics, with a price target of $4.00. The company’s shares closed last Tuesday at $1.24.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Akebia Therapeutics with a $4.67 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Idexx Laboratories (IDXX)
In a report released today, Michael Ryskin from Bank of America Securities reiterated a Hold rating on Idexx Laboratories, with a price target of $790.00. The company’s shares closed last Tuesday at $649.23.
According to TipRanks.com, Ryskin is a 3-star analyst with an average return of
Currently, the analyst consensus on Idexx Laboratories is a Moderate Buy with an average price target of $778.57.
Arvinas Holding Company (ARVN)
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Arvinas Holding Company today and set a price target of $18.00. The company’s shares closed last Tuesday at $12.37, close to its 52-week low of $7.53.
According to TipRanks.com, Fein is a 5-star analyst with an average return of
Currently, the analyst consensus on Arvinas Holding Company is a Moderate Buy with an average price target of $15.33, representing a 35.3% upside. In a report issued on February 20, Citi also maintained a Buy rating on the stock with a $15.00 price target.
